Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Marc Carrier on the WAVe Study: Weight-Adjusted Dalteparin is Safe & Effective in Large Cancer Patients with VTE
Marc Carrier/X
Nov 11, 2025, 10:51

Marc Carrier on the WAVe Study: Weight-Adjusted Dalteparin is Safe & Effective in Large Cancer Patients with VTE

Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on X:

“New in American Journal of Hematology – The WAVe Study

In patients >90 kg with cancer-associated VTE, weight-adjusted dalteparin (up to 33,000 IU/day) showed acceptable 30-Day bleeding (5.3%) and low recurrence (1.2%), supporting individualized dosing.”

Title: A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism—The WAVe Study

Authors: Tzu-Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D’Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier

Marc Carrier on the WAVe Study: Weight-Adjusted Dalteparin is Safe & Effective in Large Cancer Patients with VTE

Read full article here.

Stay updated with Hemostasis Today.

American Journal of Hematology Aurélien Delluc cancer-associated venous thromboembolism Chantal Séguin Cynthia Wu Deborah M. Siegal Erik Yeo Gregoire Le Gal Guillaume Roberge Health Hematology Hemostasis Hemostasis Today Julien D'Astous Marc Carrier Medicine Miriam Kimpton Peter L. Gross Ranjeeta Mallick Sudeep Shivakumar Tobias Tritschler Tzu-Fei Wang weight-adjusted dalteparin
NewsFeed